Talecris Underwrites Cost Of New Immune Deficiency E-Newsletter
Posted October 11, 2006
RESEARCH TRIANGLE PARK, N.C. — Talecris Biotherapeutics
is working with the Immune Deficiency Foundation to launch an electronic newsletter focused on news and information about immune deficiency.
Talecris is a manfacturer of liquid immune globulin intravenous therapy that is used to treat immune deficiency. Talecris provided a grant of an undisclosed amount to fund the newsletter.
Titled "Primary Immune Tribune," the newsletter will be delivered monthly. It will focus on resources, activities and programs and will help answer questions and provide educational information for patients and their families, the Immune Foundation said.
The first issue will be distributed this month.
"Talecris Biotherapeutics is extremely proud to be associated with such an important new informational tool," said Alberto Martinez, president and chief executive officer of Talecris. "As an industry leader with a long history of commitment to the primary immune deficiencies, Talecris recognizes the importance of collaborations, such as this one with IDF, that improve education and awareness to advance patient care. Talecris will remain a strong corporate citizen committed to these types of partnerships with the patient community."
To receive a free subscription to Primary Immune Tribune, send a request to